Renal dysfunction prevalence and clinical impact in heart failure

References

• McAlister FA, Lawson FM, Teo KK, et al. A systemic review of randomized trials of disease management programs in heart failure. Am J Med. 2001;110:378–384.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Li S, Jurkovitz CT, et al; KEEP Investigators. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008;156:277–283.
   PubMed Web of Science ®Google Scholar
• Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–2442.
   PubMed Web of Science ®Google Scholar
• Heart Failure Society of America. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12(1):e1–e2.
   Web of Science ®Google Scholar
• Drüeke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol. 2010;6:723–735.
   PubMed Web of Science ®Google Scholar
• Levin A, Djurdjev O, Barrett B, et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis. 2001;38:1398–1407.
   PubMed Web of Science ®Google Scholar
• Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125–134.
   PubMed Web of Science ®Google Scholar
• Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial. 2003;16:101–105.
   PubMed Web of Science ®Google Scholar
• Fatica RA, Dennis VW Cardiovascular mortality in chronic renal failure: hyperphosphatemia, coronary calcification, and the role of phosphate binders. Cleve Clin J Med. 2002;69(Suppl 3):S21–S27.
   Google Scholar
• Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16:529–538.
   PubMed Web of Science ®Google Scholar
• Muntner P Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004;140:9–17.
   PubMed Web of Science ®Google Scholar
• Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818–827.
   PubMed Web of Science ®Google Scholar
• De Silva R, Rigby AS, Witte KKA, et al. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol. 2006;98:391–398.
   PubMed Web of Science ®Google Scholar
• Srisawat N, Hoste EE, Kellum JA. Modern classification of acute kidney injury. Blood Purif. 2010;29:300–307.
   PubMed Web of Science ®Google Scholar
• Bagshaw SM, Cruz DN, Aspromonte N, et al; Acute Dialysis Quality Initiative (ADQI) Consensus Group. Epidemiology of cardio-renal syndromes: workgroup statements from the 7 th ADQI Consensus Conference. Nephrol Dial Transplant. 2010;25:1406–1416.
   PubMed Web of Science ®Google Scholar
• Latchamsetty R, Fang J. Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndromes. Am J Cardiol. 2007;99:939–942.
   PubMed Web of Science ®Google Scholar
• Logeart D, Tabet J. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol. 2008;127:228–232.
   PubMed Web of Science ®Google Scholar
• Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B; POSH Investigators. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J. 2006; 27:1216–1222.
   PubMed Web of Science ®Google Scholar
• Rusinaru D, Buiciuc O, Houpe D, Tribouilloy C. Renal function and long-term survival after hospital discharge in heart failure with preserved ejection fraction. Int J Cardiol. 2011;147:278–282.
   Web of Science ®Google Scholar
• Binanay C, Califf RM, Hasselblad V et al; ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625–1633.
   Google Scholar
• Klein L, Massie BM, Leimberger JD, et al; OPTIME-CHF Investigators. Heart Failure Predicts Postdischarge Survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail. 2008;1:25–33.
   PubMed Web of Science ®Google Scholar
• Smith GL, Shlipak MG, Havranek EP, et al. Serum urea nitrogen, creatinine, and estimators of renal function: mortality in older patients with cardiovascular disease. Arch Intern Med. 2006;166:1134–1142.
   PubMedGoogle Scholar
• Schrier RW. Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail. 2008;1:2–5.
   Web of Science ®Google Scholar
• Heywood JT, Fonarow GC. High prevalence of renal dysfunction and its impact on outcome in 118, 465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE Database. J Card Fail. 2007;13:422–430.
   PubMed Web of Science ®Google Scholar
• Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–596.
   PubMed Web of Science ®Google Scholar
• Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: a systematic review and meta-analysis. J Cardiac Fail. 2007;13:599–608.
   PubMed Web of Science ®Google Scholar
• Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35: 681–689.
   PubMed Web of Science ®Google Scholar
• Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J. 1999; 138(5 Pt 1):849–855.
   Web of Science ®Google Scholar
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSESS Trial Study Group. N Engl J Med. 1987;316:1429–1435.
   PubMed Web of Science ®Google Scholar
• Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–678.
   PubMed Web of Science ®Google Scholar
• Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation. 2009;120:1577–1584.
   PubMed Web of Science ®Google Scholar
• Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987–1996.
   PubMed Web of Science ®Google Scholar
• Krumolz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000;139:72–77.
   Web of Science ®Google Scholar
• Tsagalis G, Bakirtzi N, Spengos K, et al. Long-term prognosis of combined chronic heart failure and chronic renal dysfunction after acute stroke. Eur J Heart Fail. 2010;12:849–854.
   Web of Science ®Google Scholar
• Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–596.
   PubMed Web of Science ®Google Scholar
• Liang KV, Williams AW, Greene EL, Redfield MM. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med. 2008;36:S75–S88.
   PubMedGoogle Scholar
• Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–1539.
   PubMed Web of Science ®Google Scholar
• Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004;43:699–706.
   PubMed Web of Science ®Google Scholar
• Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs. 1990;39(Suppl 4):10–21.
   Google Scholar
• Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61–67.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Vassalotti JA, Collins AJ, Chen SC, Bakris GL. National Kidney Foundation’s Kidney Early Evaluation Program (KEEP) annual data report 2009: executive summary. Am J Kidney Dis. 2010;55(3 Suppl 2):S1–S3.
   Web of Science ®Google Scholar
• Lamb EJ, Tomson CR, Roderick PJ. Estimating kidney function in adults using formulae. Ann Clin Biochem. 2005;42:321–345.
   PubMed Web of Science ®Google Scholar
• Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol. 2005;16:1404–1412.
   PubMed Web of Science ®Google Scholar
• Tidman M, Sjöström P, Jones I. A comparison of GFR estimating formulae based upon s-cystatin C and s-creatinine and a combination of the two. Nephrol Dial Transplant. 2008;23:154–160.
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Lipman ML, Mann JF Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97.
   PubMed Web of Science ®Google Scholar
• Jackson CE, Solomon SD, Gerstein HC, et al; CHARM Investigators and Committees. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009;374:543–550.
   PubMed Web of Science ®Google Scholar
• Wagener G, Gubitosa G, Wang S, Borregaard N, Kim M, Lee HT. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. Am J Kidney Dis. 2008;52:425–433.
   PubMed Web of Science ®Google Scholar
• Yndestad A, Landro L, Ueland T, et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J. 2009;30:1229–1236.
   PubMed Web of Science ®Google Scholar
• Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010;16:49–54.
   PubMed Web of Science ®Google Scholar
• Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489–495.
   PubMed Web of Science ®Google Scholar
• Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009 June;53(6):961–973.
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Maggioni AP, Lucci D, et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J. 2006;27: 1207–1215.
   PubMed Web of Science ®Google Scholar
• Cody RJ. Diuretics in the management of congestive heart failure. Cardiologia. 1998;43:25–34.
   Google Scholar
• Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med. 1985;103:1–6.
   PubMed Web of Science ®Google Scholar
• Neuberg GW, Miller AB, O’Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31–38.
   PubMed Web of Science ®Google Scholar
• Abraham WT, Adams KF, Fonarow GC, et al; ADHERE Scientific Advisory Committee and Investigators and the ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005;46:57–64.
   PubMed Web of Science ®Google Scholar
• Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy during heart failure. Am Heart J. 2007;153(1): 98–104.
   Web of Science ®Google Scholar
• O’Hara JF Jr. Low-dose “renal” dopamine. Anesthesiol Clin North America. 2000;18:835–851, ix.
   Google Scholar
• Goldberg LI. Pharmacological bases for the use of dopamine and related drugs in the treatment of congestive heart failure. J Cardiovasc Pharmacol. 1989;14(Suppl 8):S21–S28.
   Google Scholar
• Kellum JA, Decker J. Use of dopamine in acute renal failure: a metaanalysis. Crit Care Med. 2001;29:1526–1531.
   PubMed Web of Science ®Google Scholar
• Ferreira A, Bettencourt P, Dias P, et al. Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. Clin Sci. 2001;100:557–566.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Cardiovascular and renal drugs advisory committee meeting transcript May 25, 2002 (3749t2. rtf). Available from: http://www.fda.gov/ohrms/dockets/ac/01/ briefing/3749b2.htm. Accessed September 28, 2001.
   Google Scholar
• Wang DJ, Dowling TC, Meadows D, et al. nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620–1625.
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Krum H, Massie BM, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure. Results of the serial infusion of nesiritide (FUSION II) trial. Circ Heart Fail. 2008; 1:9–16.
   PubMed Web of Science ®Google Scholar
• Owan TE, Chen HH, Frantz RP, et al. The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. J Card Fail. 2008 May; 14(4):267–275.
   Web of Science ®Google Scholar
• Costanzo MR, Saltzberg MT, Jessup M, Teerlink JR, Sobotka PA; Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure (UNLOAD) Investigators. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. J Card Fail. 2010;16:277–284.
   PubMed Web of Science ®Google Scholar
• Heywood JT, Fonarow GC, Yancy CW, et al. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. Am J Cardiol 2010;105:1140–1146.
   Web of Science ®Google Scholar
• Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004;110:724–731.
   PubMed Web of Science ®Google Scholar
• Ezekowitz JA, Hernandez AF, Starling RC, et al. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). Am Heart J. 2009;157(2):219–228.
   Web of Science ®Google Scholar
• Cice G, Ferrara L, DiBenedetto A, et al. Dilated cardiomyopathy in dialysis patients – beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2001;37:407^11.
   Web of Science ®Google Scholar
• Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438–1444.
   PubMed Web of Science ®Google Scholar
• Cotter G, Dittrich HC, Weatherley BD, et al; PROTECT Steering Committee Investigators, and Coordinators. The protect pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail. 2008;14:631–640.
   PubMed Web of Science ®Google Scholar
• Rosner MH. Hyponatremia in heart failure: the role of arginine vasopressin and diuretics. Cardiovasc Drugs Ther. 2009;23:307–315.
   Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–1971.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Miller AB, Blair JE, et al; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) investigators. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J. 2010;159:841–849.
   Web of Science ®Google Scholar